interferon alfa-2b


Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to interferon alfa-2b: interferon alpha, interferon alfa-2a, Intron A

interferon

 [in″ter-fēr´on]
any of a family of glycoprotein biological response modifiers used as antineoplastic agents and immunoregulators; they inhibit cellular growth, alter the state of cellular differentiation, have effects on the cell cycle, interfere with oncogene expression, alter cell surface antigen expression, have effects on antibody production, and regulate cytotoxic effector cells.
interferon-α the major interferon produced by virus-induced leukocyte cultures; its primary producer cells are null cells, and its major activities are antiviral activity and activation of NK cells.
interferon alfa-2a a synthetic form of interferon-α produced by recombinant technology that acts as a biologic response modifier, used as an antineoplastic in the treatment of hairy cell leukemia and AIDS-related Kaposi's sarcoma; administered intramuscularly or subcutaneously.
interferon alfa-2b a synthetic form of interferon-α produced by recombinant technology that acts as a biologic response modifier, used in the treatment of veneral warts, hepatitis B, and chronic hepatitis C and as an antineoplastic in the treatment of hairy cell leukemia, malignant melanoma, non-Hodgkin's lymphomas, multiple myeloma, mycosis fungoides, and AIDS-related Kaposi's sarcoma; administered intramuscularly, subcutaneously, or intralesionally.
interferon alfacon-1 a synthetic interferon related to both α and β interferons, produced by recombinant DNA technology; used in the treatment of chronic hepatitis C virus infection, administered subcutaneously.
interferon alfa-n3 a highly purified mixture of natural human interferon proteins that acts as a biologic response modifier; used in the treatment of venereal warts, administered intralesionally.
interferon-β the major interferon produced by double-stranded RNA-induced fibroblast cultures; the major producer cells are fibroblasts, epithelial cells, and macrophages, and its major activity is antiviral.
interferon beta-1a a synthetic form of interferon-β produced by recombinant DNA techniques that acts as a biologic response modifier; used in the treatment of relapsing forms of multiple sclerosis; administered intramuscularly.
interferon beta-1b a synthetic modified form of interferon-β produced by recombinant DNA techniques; used as a biologic response modifier in the treatment of relapsing forms of multiple sclerosis; administered subcutaneously.
interferon-γ the major interferon produced by lymphocyte cultures that have been immunologically stimulated by mitogens or antigens; the major producer cells are T lymphocytes, and its major activity is immunoregulation.
interferon gamma-1b a synthetic form of interferon-γ produced by recombinant technology that acts as a biologic response modifier and antineoplastic. It is used to reduce the frequency and severity of serious infections associated with chronic granulomatous disease, administered subcutaneously.

interferon alfa-2b

n.
A synthetic form of interferon alpha produced by recombinant DNA technology, used in the treatment of chronic hepatitis B and C, hairy cell leukemia, malignant melanoma, follicular lymphoma, genital warts, and AIDS-related Kaposi's sarcoma.

interferon alfa-2b

a synthetic form of interferon-α produced by recombinant technology that acts as a biological response modifier, used in the treatment of venereal warts, hepatitis B, chronic hepatitis C, and as an antineoplastic in the treatment of hairy cell leukemia, malignant melanoma, non-Hodgkin's lymphomas, multiple myeloma, mycosis fungoides, and AIDS-related Kaposi's sarcoma. It is administered intramuscularly, subcutaneously, or intralesionally.

interferon alfa-2b, recombinant

a parenteral antineoplastic drug with indications, contraindications, and adverse effects similar to those of interferon alfa-2a, recombinant.
References in periodicals archive ?
The full course of therapy will consist of an initial intravenous dose of 3 million units of interferon alfa-2b, followed 12 hours later by a subcutaneous injection of 3 million U, and then 3 million U subcutaneously every 24 hours for a total of 14 days.
A similar long-term follow-up study with pegylated interferon alfa-2b (PEGINTRON(R)) is ongoing.
Significantly more patients infected with genotype 1 or 4 hepatitis C virus (HCV) developed a sustained virologic response (SVR) with peginterferon alfa-2b (Peg-Intron) plus ribavirin (Rebetol) than with interferon alfa-2b (Intron A) plus ribavirin (17% of 125 patients vs.
Final Results of ANRS HC02-RIBAVIC: A Randomized Controlled Trial of Pegylated Interferon alfa-2b plus Ribavirin vs.
WASHINGTON -- Interferon alfa-2b reduced the severity of neurologic symptoms in patients infected with West Nile virus, according to the results of a small pilot study presented at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy.
BOSTON -- A 24-week course of pegylated interferon alfa-2b and ribavirin resulted in similar efficacy as a 48-week course for the treatment of chronic hepatitis C virus genotypes 2 and 3 in a recent study, but the shorter course was associated with significantly fewer side effects.
Side effects of interferon alfa-2b may include fever, chills, weakness, decreased white blood cell or platelet counts, increased hepatic enzyme levels, and depression.
multi-center, randomized, parallel, open-label study in 278 treatment-naive, genotype 1 patients evaluating taribavirin at weight-based doses of 20 mg/kg, 25 mg/kg, and 30 mg/kg per day in combination with pegylated interferon alfa-2b.
The researchers randomly assigned 35 treatment-naive chronic HCV patients to receive 10 million IU of interferon alfa-2b daily or the same interferon regimen plus 1,000 mg/day of ribavirin (those weighing more than 75 kg received 1,200 mg/day) for 28 days.
July 11 /PRNewswire-FirstCall/ -- Today, Schering-Plough and the EORTC announced that long-term treatment with pegylated interferon alfa-2b in stage III melanoma patients had a significant and sustained impact on relapse-free survival (RFS), according to results of a randomized phase III trial published in The Lancet today.
Pegylated interferon alfa-2b significantly suppressed viral replication and boosted immune responses in a small group of treatment-naive HIV patients in a pilot study presented at the 10th Conference on Retroviruses and Opportunistic Infections.